Jul 09, 2019
Immutep Raises A$10 Million Via Private Placement and Underwritten Entitlement Offer
Jun 25, 2019
Immutep Completes Patient Enrolment of the AIPAC Phase IIb Clinical Trial in Metastatic Breast Cancer
Jun 24, 2019
Immutep to Host Key Opinion Leader Call
Jun 20, 2019
Immutep Announces Australian Patent Granted for Eftilagimod Alpha in Chemo-Immunotherapy
Jun 13, 2019
Immutep Completes Recruitment of Initial Cohort in 1st Line NSCLC Patients for TACTI-002 Trial
Jun 05, 2019
INSIGHT: First Patient Dosed in the 4th arm called “INSIGHT-004”
Jun 02, 2019
Immutep Presentation at ASCO 2019
May 22, 2019
Immutep Announces European Patent Grant for Eftilagimod Alpha in Chemo-Immunotherapy
May 16, 2019
Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma
May 10, 2019
Immutep Announces Upcoming Industry Conference Participation
Apr 30, 2019
Operational Update
Mar 26, 2019
Immutep to Host Eftilagimod Alpha Clinical Development Update Global Webcast
Mar 20, 2019
Immutep Announces United States Patent Grant for Eftilagimod Alpha in Cancer
Mar 17, 2019
Immutep to Present IMP761 Preclinical Results in Global Webcast
Mar 06, 2019
Immutep Presents Positive IMP761 Preclinical Results at 14th Congress of European Crohn’s and Colitis Organisation
